Company Overview

Sudarshan Pharma Industries Limited (SPIL) is a specialty chemicals and pharmaceutical trading and manufacturing company founded in 2008 (18 years in operation). The company operates with the tagline "Innovating Chemistry, Empowering Health" and has global reach with exports to UK, Australia, Uzbekistan, Syria, Oman, Taiwan, and MENA regions.

Business Layout & Strategy

The company is focusing on vertical integration and increasing manufacturing capabilities. It specializes in products ranging from rock chemicals intermediates and API to finish formulations. Key clients include Intas, Minova, Invision Life sciences, Omkar Pharma, SRF, Astral Pipes, DuPont, Reliance, Bayer Corp, and Akzo Nobel.

Key Products

Specialty Green Chemicals

Acetonitrile, Tetrahydrofuran (THF), 1,4-Dioxane, DMF/DMSO, Meta xylene, N-Heptane, Diethanolamine, NMP (N-Methyl-2-pyrrolidone)

Pharma Division

  • 56 out of 96 products registered under the "R" Trade Mark
  • Novel drug delivery system under Love Bird "R" Brand featuring mouth-dissolving strips with 5 products
  • First in India launches: HART KIT LD (cardiac segment life-saving drugs for heart attacks) and SET DOWN (allopathy-ayurveda combination for constipation)
  • Top-selling brands: METFOCAL, PULMORELIEF AX, RD MAC DSR, SET DOWN, ENAMOL SP Hem D3, JIVAN KIT (Immunity Booster), Infort Q-10

Performance Chemicals & Intermediate Campaign Basis

Extensive list of 40+ specialized chemical compounds including:

  • Sesamol (3,4-(Methylenedioxy)phenol) CAS. 533-31-3 (Patent filed on April 16th, 2026)
  • Multiple other specialized chemical compounds with CAS numbers

API IN PROCESS R&D

Development pipeline includes Trimtadine, Linliptinag, Gliclazide, Eztimibee, Allopinolur, Probeidonec, Buivainepca, Roivainepca, Brivataracem, Vigbaintra, Lidocaineca, and 20+ other API molecules

Export Performance & Targets

  • FY 25-26: Achieved export turnover of ₹21.85 Cr focusing on own manufacturing API products (including oncology) and finish formulations
  • FY 26-27: Target minimum ₹100 Cr by strengthening segments and targeting regulated/semi-regulated markets, increasing high-value API product range for Europe and USA markets
  • FY 27-28: Plan to strengthen OTC and regulated markets, form depots in various countries, and increase finish formulation registration in regulated markets

Manufacturing Facilities

Hyderabad Unit

Bulk drug & intermediate manufacturing unit with:

  • Developed about 50 potential API Key Starting Materials
  • Outstanding commercial technology
  • Patent rights on few key starting materials
  • Reactor capacity in manufacturing facility
  • Contract manufacturing GMP facility located at Hyderabad
  • Achieved GMP certification for API intermediates and active pharmaceutical ingredients
  • ISO 9001:2015 certification for quality management system

Subsidiaries & Acquisitions

Ratna Lifescience

Successful turnaround story - prior to take-over, Ratna Life was operating at a loss. Since takeover by the company, it has turned into a profitable organization with significant growth in PAT.

Management & Leadership

Board of Directors

  • Mr. Hemal V. Mehta: Chairman & Managing Director (26 years experience)
  • Mr. Sachin V. Mehta: Joint Managing Director
  • Mr. Vijay Ojha: Independent Director (29+ years industrial experience)
  • Ms. Jaya Singhania: Independent Director (listed as Top Best Ten Women Legal Consultants in India 2021)
  • Adv. Rushabh Patil: Independent Director (Practicing Advocate in Bombay High Court)
  • Mr. Anil Ghoghare: Non-Executive Director (37+ years experience, Pharma-In-Future Technology)
  • Mr. Sanat Bhat: Independent Director (Chartered Accountant with 13+ years experience)
  • Dr. Vinay Pandey: Non-Executive Director (Geotechnical expert with 24+ years experience)

Chief Financial Officer

Mr. Sharad Kathawate: CFO with over 25 years experience, qualifications in M.Com, LLB, AICAI, MBA (Finance) and CS (Final). Expertise in IPO execution, financial structuring, and listing management.

Senior Consultants & Key Personnel

List of 23+ senior consultants and key personnel across various functions including R&D, imports, exports, finance, purchase, quality control, and business development.

Strategic Partnerships

Amity University Collaboration

Strategic partnership with Dr. William Selvamurthy at Amity University covering:

  • Joint initiatives in Nanotechnology
  • Collaborative Pharmaceutical and Healthcare R&D
  • Partnership in Patent writing and submission
  • Commercialization of innovative technologies and R&D products
  • Engagement in clinical studies and patent filings

SPIL honored with "Amity Shield" and "Airavata" mementos from Dr. Tinku Basu, Director of Amity University.

Market Context & Opportunity

Government Support

The central government has earmarked approximately ₹100 billion for the bulk drug industry, including:

  • ₹30 billion for promotion of bulk drug parks (next five years)
  • ₹69.4 billion for production-linked incentive scheme for domestic manufacturing of critical KSMs/Drug Intermediates and APIs (next eight years)

The scheme identified 53 critical APIs/Intermediates where India's reliance on China is high.

China Dependency Challenge

  • India imports ~70% of Intermediate required for APIs from China
  • 75-80% dependency for Antibiotics
  • 80-85% dependency for Organic heterocyclic compounds
  • 70-75% dependency for Organic compounds
  • Pandemic caused supply disruptions and price rises
  • Environmental norm failures in China affecting chemical companies
  • Chinese industry receives extensive government subsidies

Financial Performance

Consolidated Profit & Loss (Unaudited Sep 2026)

  • Revenue from Operations: ₹391.39 Cr (Sep 2026) vs ₹314.13 Cr (Sep 2025)
  • Cost of Materials Consumed: ₹215.4 Cr
  • Purchase of Stock-in-Trade: ₹360.86 Cr
  • Changes in Inventories: -₹42.50 Cr
  • Gross Profit: ₹57.80 Cr (14.77% margin)
  • EBITDA: ₹39.63 Cr (10.13% margin)
  • Other Income: ₹3.15 Cr
  • Depreciation: ₹2.76 Cr
  • Finance Costs: ₹18.56 Cr
  • PBT: ₹18.31 Cr (4.68% margin)
  • Tax: ₹4.92 Cr
  • PAT: ₹13.39 Cr (3.42% margin)
  • EPS: ₹0.54

Historical Financials (Audited FYE Mar 2026)

  • Revenue: ₹703.06 Cr (FY26) vs ₹505.05 Cr (FY25) vs ₹463.54 Cr (FY24)
  • PAT: ₹23.30 Cr (FY26) vs ₹15.88 Cr (FY25) vs ₹11.46 Cr (FY24)
  • EPS: ₹0.97 (FY26) vs ₹0.66 (FY25)

Balance Sheet (Mar 2026)

  • Share Capital: ₹24.07 Cr
  • Reserves and Surplus: ₹132.25 Cr
  • Long-Term Borrowings: ₹38.37 Cr
  • Short-Term Borrowings: ₹255.11 Cr
  • Total Equity & Liabilities: ₹641.75 Cr
  • Fixed Assets: ₹96.03 Cr
  • Investments: ₹218.74 Cr
  • Total Assets: ₹641.75 Cr

Investment Thesis

The presentation positions Sudarshan Pharma as addressing market pain points caused by high dependency on China for raw materials of specialty chemicals, intermediates and excipients. The company offers cost stability, supply chain resilience, tariff risk mitigation, and regulatory-ready documentation for global markets.